Nicotinamide Phosphoribosyltransferase in Malignancy: A Review

Genes and Cancer

Volumn 4, Issue 11-12, 2013, Pages 447-456

  Shackelford, Rodney E ^a   Mayhall, Kim ^b   Maxwell, Nicole M ^c   Kandil, Emad ^b   Coppola, Domenico ^d  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Independent Researcher   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

human cancer; nicotinamide adenine dinucleotide; nicotinamide phosphoribosyltransferase

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CD38 ANTIGEN; CTBP PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA REPAIR; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; METASTASIS; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84891510983     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913507576     Document Type: Review

References (112)

1. Berger F,Ramírez-Hernández MH,Ziegler M.The new life of a centenarian: signalling functions of NAD(P).Trends Biochem Sci. 2004;29:111-8.
2. Preiss J,Handler P.Enzymatic synthesis of nicotinamide mononucleotide.J Biol Chem. 1957;225:759-70.
3. Gholson RK.The pyridine nucleotide cycle.Nature. 1966;212:933-34.
4. Rechsteiner M,Hillyard D,Olivera BM.Magnitude and significance of NAD turnover in human cell line D98/AH2.Nature. 1976;259:695-6.
5. Samal B,Sun Y,Stearns G,Xie C,Suggs S,McNiece I.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol. 1994;14:1431-7.
6. Jia SH,Li Y,Parodo J, et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest. 2004;113:1318-27.
7. Fukuhara A,Matsuda M,Nishizawa M, et al.Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.Science. 2005;307:426-30.
8. Fukuhara A,Matsuda M,Nishizawa M, et al.Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.Science. 2007;318:565.
9. Martin PR,Shea RJ,Mulks MH.Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence.J Bacteriol. 2001;183:1168-74.
10. Rongvaux A,Shea RJ,Mulks MH, et al.Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis.Eur J Immunol. 2002;32:3225-34.
11. Revollo JR,Grimm AA,Imai S.The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.J Biol Chem. 2004;279:50754-63.
12. Olesen UH,Thougaard AV,Jensen PB,Sehested M.A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyl-transferase inhibitor.Mol Cancer Ther. 2010;9:1609-17.
13. Kitani T,Okuno S,Fujisawa H.Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.FEBS Lett. 2003;544:74-8.
14. Zhang Y,Dorweiler B,Cui D, et al.Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.J Biol Chem. 2008;283:34833-43.
15. Yang H,Yang T,Baur JA, et al.Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival.Cell. 2007;130:1095-107.
16. Nikiforov A,Dölle C,Niere M,Ziegler M.Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation.J Biol Chem. 2011;286:21767-78.
17. Revollo JR,Körner A,Mills KF, et al.Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme.Cell Metab. 2007;6:363-75.
18. Ruiz JR,Lasa A,Simon E,Larrarte E,Labayen I.Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.Nutr Metab Cardiovasc Dis. 2012;22:e1-e2.
19. Hara N,Yamada K,Shibata T,Osago H,Tsuchiya M.Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma.PLoS One. 2011;6:e22781.
20. Garten A,Petzold S,Körner A,Imai S,Kiess W.Nampt: linking NAD biology, metabolism and cancer.Trends Endocrinol Metab. 2009;20:130-8.
21. Haider DG,Schaller G,Kapiotis S,Maier C,Luger A,Wolzt M.The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia. 2006;49:1909-14.
22. Tanaka M,Nozaki M,Fukuhara A, et al.Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway.Biochem Biophys Res Commun. 2007;359:194-201.
23. Storka A,Vojtassakova E,Mueller M, et al.Angiotensin inhibition stimulates PPARgamma and the release of visfatin.Eur J Clin Invest. 2008;38:820-6.
24. Garten A,Petzold S,Barnikol-Oettler A, et al.Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes.Biochem Biophys Res Commun. 2010;391:376-81.
25. Pillai VB,Sundaresan NR,Kim G, et al.Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.Am J Physiol Heart Circ Physiol. 2013;304:H415-26.
26. Ognjanovic S,Bao S,Yamamoto SY,Garibay-Tupas J,Samal B,Bryant-Greenwood GD.Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes.J Mol Endocrinol. 2001;26:107-17.
27. McGlothlin JR,Gao L,Lavoie T, et al.Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.Biochem Genet. 2005;43:127-41.
28. Wang T,Zhang X,Bheda P,Revollo JR,Imai S,Wolberger C.Structure of Nampt/PBEF/visfatin, a mammalian NAD(+) biosynthetic enzyme.Nat Struct Mol Biol. 2006;13:661-2.
29. Burgos ES,Ho MC,Almo SC,Schramm VL.A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT.Proc Natl Acad Sci U S A. 2009;106:13748-53.
30. Warburg O,Christian W,Griese A.Wasserstoffuebertra-gendes Co-Ferment, seine Zusammensetzung und wirkungs weise.Biochem Z. 1935;282:157-65.
31. Lin SJ,Guarente L.Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease.Curr Opin Cell Biol. 2003;15:241-6.
32. Sebastián C,Satterstrom FK,Haigis MC,Mostoslavsky R.From sirtuin biology to human diseases: an update.J Biol Chem. 2012;287:42444-52.
33. Chiarugi A,Dölle C,Felici R,Ziegler M.The NAD metabolome-a key determinant of cancer cell biology.Nat Rev Cancer. 2012;12:741-52.
34. Chinnadurai G.The transcriptional corepressor CtBP: a foe of multiple tumor suppressors.Cancer Res. 2009;69:731-4.
35. Malavasi F,Deaglio S,Funaro A, et al.Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.Physiol Rev. 2008;88:841-86.
36. Bürkle A,Virág L.Poly(ADP-ribose): PARadigms and PARadoxes.Mol Aspects Med. 2013;S0098-2997:00157-4.
37. Hufton SE,Moerkerk PT,Brandwijk R,de Bruïne AP,Arends JW,Hoogenboom HR.A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization.FEBS Lett. 1999;463:77-82.
38. Van Beijnum JR,Moerkerk PT,Gerbers AJ, et al.Target validation for genomics using peptide-specific phage antibodies. A study of five gene products overexpressed in colorectal cancer.Int J Cancer. 2002;101:118-27.
39. Shackelford RE,Bui MM,Coppola D,Hakam A.Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.Int J Clin Exp Pathol. 2010;3:522-7.
40. Folgueira MA,Carraro DM,Brentani H, et al.Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.Clin Cancer Res. 2005;11:7434-43.
41. Bae SK,Kim SR,Kim JG, et al.Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.FEBS Lett. 2006;580:4105-13.
42. Kim JG,Kim EO,Jeong BR, et al.Visfatin stimulates proliferation of MCF-7 human breast cancer cells.Mol Cells. 2010;30:341-5.
43. Bi TQ,Che XM,Liao XH, et al.Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.Oncol Rep. 2011;26:1251-7.
44. Long HL,Che XM,Bi TQ,Li HJ,Liu JS,Li DW.The expression of nicotinamide phosphoribosyl transferase and vascular endothelial growth factor-A in gastric carcinoma and their clinical significance.Zhonghua Wai Ke Za Zhi. 2012;50:839-42.
45. Wang B,Hasan MK,Alvarado E,Yuan H,Wu H,Chen WY.NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.Oncogene. 2011;30:907-21.
46. Patel ST,Mistry T,Brown JE, et al.A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis.Peptides. 2010;31:51-7.
47. Tian W,Zhu Y,Wang Y, et al.Visfatin, a potential biomarker and prognostic factor for endometrial cancer.Gynecol Oncol. 2013;129:505-12.
48. Maldi E,Travelli C,Caldarelli A, et al.Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.Pigment Cell Melanoma Res. 2013;26:144-6.
49. Bułdak RJ,Bułdak Ł,Polaniak R, et al.Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.Oncol Rep. 2013;29:771-8.
50. Venkateshaiah SU,Khan S,Ling W, et al.NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.Exp Hematol. 2013;41:547-57.e2.
51. Ni IB,Ching NC,Meng CK,Zakaria Z.Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.Hematol Rep. 2012;4:e19.
52. Reddy PS,Umesh S,Thota B, et al.PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.Cancer Biol Ther. 2008;7:663-8.
53. Ninomiya S,Shimizu M,Imai K, et al.Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.Cancer Prev Res (Phila). 2011;4:2092-100.
54. Shackelford R,Hirsh S,Henry K,Abdel-Mageed A,Kandil E,Coppola D.Nicotinamide phosphoribosyltransferase and SirT3 expression are increased in well-differentiated thyroid carcinomas.Anticancer Res. 2013;33:3047-52.
55. Olesen UH,Hastrup N,Sehested M.Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.APMIS. 2011;119:296-303.
56. Huang WS,Chen CN,Sze CI,Teng CC.Visfatin induces stromal cell-derived factor-1 expression by β1 integrin signaling in colorectal cancer cells.J Cell Physiol. 2013;228:1017-24.
57. Mayhall K,Ghayouri M,Hemry K,Margin V,Copolla D,Shackelford R.Thirty-five-year old woman with signet ring cell gastric carcinoma secondary to the Chernobyl nuclear accident: a case report.Case Rep Oncol. 2013;6:158-62.
58. Singh N.Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancers.Cancer Lett. 1991;58:131-5.
59. Song NY,Surh YJ.Janus-faced role of SIRT1 in tumorigenesis.Ann N Y Acad Sci. 2012;1271:10-9.
60. Carafa V,Nebbioso A,Altucci L.Sirtuins and disease: the road ahead.Front Pharmacol. 2012;3:4.
61. Alhazzazi TY,Kamarajan P,Verdin E,Kapila YL.SIRT3 and cancer: tumor promoter or suppressor?.Biochim Biophys Acta. 2011;1816:80-8.
62. Di LJ,Byun JS,Wong MM, et al.Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.Nat Commun. 2013;4:1449.
63. Zhao LZ,Chinnadurai G.Incapacitating CtBP to kill cancer.Cell Cycle. 2010;9:3645-6.
64. Zhang Q,Piston DW,Goodman RH.Regulation of corepressor function by nuclear NADH.Science. 2002;295:1895-7.
65. Zhang Q,Wang SY,Nottke AC,Rocheleau JV,Piston DW,Goodman RH.Redox sensor CtBP mediates hypoxia-induced tumor cell migration.Proc Natl Acad Sci U S A. 2006;103:9029-33.
66. Paliwal S,Ho N,Parker D,Grossman SR.CtBP2 promotes human cancer cell migration by transcriptional activation of Tiam1.Genes Cancer. 2012;3:481-90.
67. van Horssen R,Willemse M,Haeger A, et al.Intracellular NAD(H) levels control motility and invasion of glioma cells.Cell Mol Life Sci. 2013;70:2175-90.
68. van der Veer MS,de Weers M,van Kessel B, et al.The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.Blood Cancer J. 2011;1:e41.
69. Chillemi A,Zaccarello G,Quarona V, et al.Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.Mol Med. 2013;19:99-108.
70. Nahimana A,Attinger A,Aubry D, et al.The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.Blood. 2009;113:3276-86.
71. Lockett KL,Hall MC,Xu J, et al.The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.Cancer Res. 2004;64:6344-8.
72. Zhang X,Miao X,Liang G, et al.Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer.Cancer Res. 2005;65:722-6.
73. Hao B,Wang H,Zhou K, et al.Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma.Cancer Res. 2004;64:4378-84.
74. Zaremba T,Ketzer P,Cole M,Coulthard S,Plummer ER,Curtin NJ.Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.Br J Cancer. 2009;101:256-62.
75. Berger NA,Sims JL,Catino DM,Berger SJ.Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: studies in normal and DNA-repair defective cells.Princess Takamatsu Symp. 1983;13:219-26.
76. Mathews MT,Berk BC.PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.Arterioscler Thromb Vasc Biol. 2008;28:711-7.
77. Virág L,Scott GS,Cuzzocrea S,Marmer D,Salzman AL,Szabo C.Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly(ADP-ribose) synthetase (PARS) activation.Immunology. 1998;94:345-55.
78. Bajrami I,Kigozi A,Van Weverwijk A, et al.Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.EMBO Mol Med. 2012;4:1087-96.
79. Papeo G,Casale E,Montagnoli A,Cirla A.PARP inhibitors in cancer therapy: an update.Expert Opin Ther Pat. 2013;23:503-14.
80. Pillai JB,Russell HM,Raman J,Jeevanandam V,Gupta MP.Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.Am J Physiol Heart Circ Physiol. 2005;288:486-96.
81. Zhang J.Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked?.Bioessays. 2003;25:808-14.
82. Kolthur-Seetharam U,Dantzer F,McBurney MW,de Murcia G,Sassone-Corsi P.Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage.Cell Cycle. 2006;5:873-7.
83. Rajamohan SB,Pillai VB,Gupta M, et al.SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1.Mol Cell Biol. 2009;29:4116-29.
84. Hirai K,Ueda K,Hayaishi O.Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.Cancer Res. 1983;43:3441-6.
85. Rojo F,García-Parra J,Zazo S, et al.Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.Ann Oncol. 2012;23:1156-4.
86. Ossovskaya V,Koo IC,Kaldjian EP,Alvares C,Sherman BM.Upregulation of poly (ADP-Ribose) Polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types.Genes Cancer. 2010;1:812-21.
87. Galia A,Calogero AE,Condorelli R, et al.PARP-1 protein expression in glioblastoma multiforme.Eur J Histochem. 2012;56:e9.
88. Ikai K,Ueda K,Fukushima M,Nakamura T,Hayaishi O.Poly(ADP-ribose) synthesis, a marker of granulocyte differentiation.Proc Natl Acad Sci U S A. 1980;77:3682-5.
89. Thomas C,Pfirrmann K,Pieles F, et al.Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.BJU Int. 2012;109:214-9.
90. Fazeli MS,Dashti H,Akbarzadeh S, et al.Circulating levels of novel adipocytokines in patients with colorectal cancer.Cytokine. 2013;62:81-5.
91. Nakajima TE,Yamada Y,Hamano T, et al.Adipocytokine levels in gastric cancer patients. Resistin and visfatin as biomarkers of gastric cancer.J Gastroenterol. 2009;44:685-90.
92. Yu-Duan T,Chao-Ping W,Chih-Yu C, et al.Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.Med Oral Patol Oral Cir Bucal. 2013;18:e180-6.
93. Dalamaga M,Archondakis S,Sotiropoulos G, et al.Could serum visfatin be a potential biomarker for postmenopausal breast cancer?.Maturitas. 2012;71:301-8.
94. Yammani RR,Loeser RF.Extracellular nicotinamide phosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes.Arthritis Res Ther. 2012;1:R23.
95. Dahl TB,Yndestad A,Skjelland M, et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.Circulation. 2007;115:972-80.
96. Moschen AR,Kaser A,Enrich B, et al.Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.J Immunol. 2007;178:1748-58.
97. Kendal CE,Bryant-Greenwood GD.Pre-B-cell colony-enhancing factor (PBEF/visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells.Placenta. 2007;28:305-14.
98. Stark GR,Darnell JE.The JAK-STAT pathway at twenty.Immunity. 2012;36:503-14.
99. Bromberg JF,Wrzeszczynska MH,Devgan G, et al.Stat3 as an oncogene.Cell. 1999;98:295-303.
100. Vendramini-Costa DB,Carvalho JE.Molecular link mechanisms between inflammation and cancer.Curr Pharm Des. 2012;18:3831-52.
101. Waldner MJ,Foersch S,Neurath MF.Interleukin-6-a key regulator of colorectal cancer development.Int J Biol Sci. 2012;8:1248-53.
102. Hasmann M,Schemainda I.FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.Cancer Res. 2003;63:7436-42.
103. Clark JB,Ferris GM,Pinder S.Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide.Biochim Biophys Acta. 1971;238:82-85.
104. Jackson MD,Schmidt MT,Oppenheimer NJ,Denu JM.Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases.J Biol Chem. 2003;278:50985-98.
105. Sauve AA,Schramm VL.Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry.Biochemistry. 2003;42:9249-56.
106. Bi TQ,Che XM.Nampt/PBEF/visfatin and cancer.Cancer Biol Ther. 2010;10:119-25.
107. Okumura S,Sasaki T,Minami Y,Ohsaki Y.Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.J Thorac Oncol. 2012;7:49-56.
108. Wosikowski K,Mattern K,Schemainda I,Hasmann M,Rattel B,Löser R.WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.Cancer Res. 2002;62:1057-62.
109. Zoppoli G,Cea M,Soncini D, et al.Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.Exp Hematol. 2010;38:979-88.
110. Zhang LY,Liu LY,Qie LL, et al.Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.Eur J Pharmacol. 2012;674:163-70.
111. Iglehart JD,Silver DP.Synthetic lethality-a new direction in cancer-drug development.N Engl J Med. 2009;361:189-91.
112. Santidrian AF,Matsuno-Yagi A,Ritland M, et al.Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.J Clin Invest. 2013;123:1068-81.